Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08FNJ
|
||||
| Former ID |
DIB006001
|
||||
| Drug Name |
RO-14
|
||||
| Synonyms |
Very low molecular weight heparin (venous thromboembolism), Rovi
|
||||
| Indication | Phlebothrombosis [ICD10:I80-I82] | Phase 1 | [1] | ||
| Company |
Laboratorios Farmaceuticos Rovi SA
|
||||
| Target and Pathway | |||||
| Target(s) | Antithrombin-III | Target Info | Modulator | [2] | |
| KEGG Pathway | Complement and coagulation cascades | ||||
| PANTHER Pathway | Blood coagulation | ||||
| Pathway Interaction Database | Glypican 1 network | ||||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | ||||
| Common Pathway of Fibrin Clot Formation | |||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| Formation of Fibrin Clot (Clotting Cascade) | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00629733) Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers. U.S. National Institutes of Health. | ||||
| REF 2 | Pharmacological effects and clinical applications of ultra low molecular weight heparins. Drug Discov Ther. 2014 Feb;8(1):1-10. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.